Literature DB >> 16857788

Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population.

Shao Hui Tang1, Dong Hua Yang, Wei Huang, Hong Ke Zhou, Xiao Hua Lu, Gang Ye.   

Abstract

PURPOSE: The expression of human insulin-like growth factor-II (IGF-II) is regulated by the activation of four promoters (P1-P4) acting in a development-dependent, tissue-specific manner. IGF-II overexpression associated with P3 and P4 activation is observed in animal and human hepatocarcinogenesis. We correlated P4 epigenetic alteration with P4 transcript activation and clinicopathologic features. EXPERIMENTAL
DESIGN: We analyzed P4 epigenetic alteration using methylation-specific PCR in 34 hepatocellular carcinoma (HCC) specimens, 34 matched adjacent nontumor specimens, and 8 normal adult liver specimens. The data were correlated with activation of P4 transcription by using reverse transcription-PCR. Epigenetic alteration was compared with patients' clinicopathologic features.
RESULTS: Compared with normal liver tissue, hypomethylation of P4 CpG islands was significantly more frequent in HCC (P = 0.03) and matched tissues (P = 0.047). P4 mRNA levels in HCC with unmethylated alleles were significantly higher than in HCC without unmethylated alleles (P = 0.001); P4 mRNA levels in matched nontumor tissues with unmethylated alleles were significantly higher than in matched nontumor tissues without unmethylated alleles (P = 0.005). P4 hypomethylation in HCC was associated with portal vein tumor embolus (P = 0.017) and poorer tumor differentiation (P = 0.025).
CONCLUSIONS: These findings suggest that IGF-II P4 hypomethylation may be an early and frequent event and that it may contribute to P4 transcription expression activation during the transformation of a premalignant liver lesion to HCC. Furthermore, aberrant hypomethylation of P4 CpG islands not only may play an important role during hepatocarcinogenesis but might also be a useful biomarker for poor prognosis of patients with HCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16857788     DOI: 10.1158/1078-0432.CCR-05-2261

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

Review 1.  DNA hypomethylation in the origin and pathogenesis of human diseases.

Authors:  Igor P Pogribny; Frederick A Beland
Journal:  Cell Mol Life Sci       Date:  2009-03-27       Impact factor: 9.261

Review 2.  Next-generation sequencing and personalized genomic medicine in hepatobiliary malignancies.

Authors:  Arturo Loaiza-Bonilla; Emma E Furth; Jennifer Jd Morrissette
Journal:  Hepat Oncol       Date:  2015-11-11

Review 3.  Cancer gene discovery in hepatocellular carcinoma.

Authors:  Lars Zender; Augusto Villanueva; Victoria Tovar; Daniela Sia; Derek Y Chiang; Josep M Llovet
Journal:  J Hepatol       Date:  2010-03-20       Impact factor: 25.083

4.  IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

Authors:  Victoria Tovar; Clara Alsinet; Augusto Villanueva; Yujin Hoshida; Derek Y Chiang; Manel Solé; Swan Thung; Susana Moyano; Sara Toffanin; Beatriz Mínguez; Laia Cabellos; Judit Peix; Myron Schwartz; Vincenzo Mazzaferro; Jordi Bruix; Josep M Llovet
Journal:  J Hepatol       Date:  2010-02-13       Impact factor: 25.083

Review 5.  Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Authors:  Kai Breuhahn; Peter Schirmacher
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

6.  Altered microRNA Expression Patterns in Hepatoblastoma Patients.

Authors:  Armando Magrelli; Gianluca Azzalin; Marco Salvatore; Mara Viganotti; Fabrizio Tosto; Teresa Colombo; Rita Devito; Alessandra Di Masi; Antonio Antoccia; Stefano Lorenzetti; Francesca Maranghi; Alberto Mantovani; Caterina Tanzarella; Giuseppe Macino; Domenica Taruscio
Journal:  Transl Oncol       Date:  2009-08-18       Impact factor: 4.243

7.  Whole-exome sequencing identifies mutated PCK2 and HUWE1 associated with carcinoma cell proliferation in a hepatocellular carcinoma patient.

Authors:  Yan-Xuan Liu; Shu-Fang Zhang; Ying-Hua Ji; Sheng-Ju Guo; Geng-Fu Wang; Guang-Wen Zhang
Journal:  Oncol Lett       Date:  2012-07-26       Impact factor: 2.967

8.  Anti-insulin-like growth factor-IIP3 DNAzymes inhibit cell proliferation and induce caspase-dependent apoptosis in human hepatocarcinoma cell lines.

Authors:  Min Zhang; Gregor P C Drummen; Su Luo
Journal:  Drug Des Devel Ther       Date:  2013-10-04       Impact factor: 4.162

9.  Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma.

Authors:  Jiliang Qiu; Pinzhu Huang; Qian Liu; Jian Hong; Binkui Li; Canliang Lu; Li Wang; Jianping Wang; Yunfei Yuan
Journal:  J Transl Med       Date:  2011-09-29       Impact factor: 5.531

10.  Genome-wide and gene-specific epigenomic platforms for hepatocellular carcinoma biomarker development trials.

Authors:  Christina Michailidi; Ethan Soudry; Mariana Brait; Leonel Maldonado; Andrew Jaffe; Carmen Ili-Gangas; Priscilla Brebi-Mieville; Jimena Perez; Myoung Sook Kim; Xiaoli Zhong; Quiang Yang; Blanca Valle; Stephen J Meltzer; Michael Torbenson; Manel Esteller; David Sidransky; Rafael Guerrero-Preston
Journal:  Gastroenterol Res Pract       Date:  2014-04-17       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.